Overview and Scope
The pancreatic cancer drugs refers to the medications or drugs that are used to treat pancreatic cancer which is caused by the unrestrained growth of cells in the pancreas, thus disrupting the production of digestive juices and hormones responsible to regulate the blood sugar level in the body. This abnormal growth of cells leads to tissue lumps referred to as tumors. The presence of tumors hinders normal pancreas functioning.
Sizing and Forecast
The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.83 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer.
The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support. Major trends in the forecast period include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Segmentation & Regional Insights
The pancreatic cancer drugs market covered in this report is segmented –
1) By Type: Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs
2) By Drug Combination: Single, Double, Triplet, Quadruplet
3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
North America was the largest region in the pancreatic cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=2565&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs market. With the rise in several pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the pancreatic cancer drugs market. The number of cancer cases has increased mainly due to the aging population and an increase in several people suffering from obesity. For instance, according to the American Cancer Society, in 2023 estimated about 64,050 people (33,130 men and 30,920 women) will be diagnosed with pancreatic cancer and about 50,550 people (26,620 men and 23,930 women) will die of pancreatic cancer .
Key Industry Players
Major companies operating in the pancreatic cancer drugs market report are Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, AbbVie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd., Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd., Swisschem Healthcare Pvt Ltd., Apikos Pharma, Kolaz Biotech, Aqvida Gmbh, Baxter International Inc (Uk), Glaxosmithkline PLC, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer Ag, Eurofarma Laboratórios S.A, Tuteur Argentina, Neopharma Llc, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology, Adcock Ingram
The pancreatic cancer drugs market report table of contents includes:
1. Executive Summary
2. Pancreatic Cancer Drugs Market Characteristics
3. Pancreatic Cancer Drugs Market Trends And Strategies
4. Pancreatic Cancer Drugs Market – Macro Economic Scenario
5. Global Pancreatic Cancer Drugs Market Size and Growth
.
.
.
31. Pancreatic Cancer Drugs Market Other Major And Innovative Companies
32. Global Pancreatic Cancer Drugs Market Competitive Benchmarking
33. Global Pancreatic Cancer Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Pancreatic Cancer Drugs Market
35. Pancreatic Cancer Drugs Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
